Pharmacy and therapeutics committee review of encainide

P. H. Vlasses, D. M. Roden, D. P. Zipes, S. R. Kayser

Research output: Contribution to journalArticle

Abstract

A mock pharmacy and therapeutics committee evaluation of encainide is presented. In evaluating a new drug for formulary inclusion, the first question is whether it is effective for the stated indications. Then, the role of the new drug relative to standard therapy should be considered. With encainide, as with other antiarrhythmic agents, determination of the superiority of a drug is difficult because results of comparative studies are strongly influenced by criteria for efficay, characteristics of the patient population, and the study design. Encainide appears to be similar in efficacy to flecainide, disopyramide, quinidine, and procainamide. Proarrhythmic and other adverse effects are important considerations with antiarrhythmic agents. A decision as to whether the new drug is a first-line agent must be made, and the need for implementation of methods for ensuring appropriate use must be considered. Beneficial and undesirable effects of one method, restricted prescribing, are discussed. Evaluation of new antiarrhythmic agents is a complex process.

Original languageEnglish (US)
Pages (from-to)23-25
Number of pages3
JournalClinical Pharmacy
Volume6
Issue number3 II
StatePublished - 1987
Externally publishedYes

Fingerprint

Encainide
Pharmacy and Therapeutics Committee
Pharmaceutical Preparations
Flecainide
Disopyramide
Procainamide
Formularies
Quinidine
Population Characteristics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Vlasses, P. H., Roden, D. M., Zipes, D. P., & Kayser, S. R. (1987). Pharmacy and therapeutics committee review of encainide. Clinical Pharmacy, 6(3 II), 23-25.

Pharmacy and therapeutics committee review of encainide. / Vlasses, P. H.; Roden, D. M.; Zipes, D. P.; Kayser, S. R.

In: Clinical Pharmacy, Vol. 6, No. 3 II, 1987, p. 23-25.

Research output: Contribution to journalArticle

Vlasses, PH, Roden, DM, Zipes, DP & Kayser, SR 1987, 'Pharmacy and therapeutics committee review of encainide', Clinical Pharmacy, vol. 6, no. 3 II, pp. 23-25.
Vlasses PH, Roden DM, Zipes DP, Kayser SR. Pharmacy and therapeutics committee review of encainide. Clinical Pharmacy. 1987;6(3 II):23-25.
Vlasses, P. H. ; Roden, D. M. ; Zipes, D. P. ; Kayser, S. R. / Pharmacy and therapeutics committee review of encainide. In: Clinical Pharmacy. 1987 ; Vol. 6, No. 3 II. pp. 23-25.
@article{9d5c4b564f8f45b9bab3a965a2bd83d4,
title = "Pharmacy and therapeutics committee review of encainide",
abstract = "A mock pharmacy and therapeutics committee evaluation of encainide is presented. In evaluating a new drug for formulary inclusion, the first question is whether it is effective for the stated indications. Then, the role of the new drug relative to standard therapy should be considered. With encainide, as with other antiarrhythmic agents, determination of the superiority of a drug is difficult because results of comparative studies are strongly influenced by criteria for efficay, characteristics of the patient population, and the study design. Encainide appears to be similar in efficacy to flecainide, disopyramide, quinidine, and procainamide. Proarrhythmic and other adverse effects are important considerations with antiarrhythmic agents. A decision as to whether the new drug is a first-line agent must be made, and the need for implementation of methods for ensuring appropriate use must be considered. Beneficial and undesirable effects of one method, restricted prescribing, are discussed. Evaluation of new antiarrhythmic agents is a complex process.",
author = "Vlasses, {P. H.} and Roden, {D. M.} and Zipes, {D. P.} and Kayser, {S. R.}",
year = "1987",
language = "English (US)",
volume = "6",
pages = "23--25",
journal = "Clinical Pharmacy",
issn = "0278-2677",
publisher = "American Society of Hospital Pharmacists",
number = "3 II",

}

TY - JOUR

T1 - Pharmacy and therapeutics committee review of encainide

AU - Vlasses, P. H.

AU - Roden, D. M.

AU - Zipes, D. P.

AU - Kayser, S. R.

PY - 1987

Y1 - 1987

N2 - A mock pharmacy and therapeutics committee evaluation of encainide is presented. In evaluating a new drug for formulary inclusion, the first question is whether it is effective for the stated indications. Then, the role of the new drug relative to standard therapy should be considered. With encainide, as with other antiarrhythmic agents, determination of the superiority of a drug is difficult because results of comparative studies are strongly influenced by criteria for efficay, characteristics of the patient population, and the study design. Encainide appears to be similar in efficacy to flecainide, disopyramide, quinidine, and procainamide. Proarrhythmic and other adverse effects are important considerations with antiarrhythmic agents. A decision as to whether the new drug is a first-line agent must be made, and the need for implementation of methods for ensuring appropriate use must be considered. Beneficial and undesirable effects of one method, restricted prescribing, are discussed. Evaluation of new antiarrhythmic agents is a complex process.

AB - A mock pharmacy and therapeutics committee evaluation of encainide is presented. In evaluating a new drug for formulary inclusion, the first question is whether it is effective for the stated indications. Then, the role of the new drug relative to standard therapy should be considered. With encainide, as with other antiarrhythmic agents, determination of the superiority of a drug is difficult because results of comparative studies are strongly influenced by criteria for efficay, characteristics of the patient population, and the study design. Encainide appears to be similar in efficacy to flecainide, disopyramide, quinidine, and procainamide. Proarrhythmic and other adverse effects are important considerations with antiarrhythmic agents. A decision as to whether the new drug is a first-line agent must be made, and the need for implementation of methods for ensuring appropriate use must be considered. Beneficial and undesirable effects of one method, restricted prescribing, are discussed. Evaluation of new antiarrhythmic agents is a complex process.

UR - http://www.scopus.com/inward/record.url?scp=0023234512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023234512&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023234512

VL - 6

SP - 23

EP - 25

JO - Clinical Pharmacy

JF - Clinical Pharmacy

SN - 0278-2677

IS - 3 II

ER -